BirchBioMed Inc., a clinical-stage biomedical company focused on the clinical evaluation, development and commercialization of anti-scarring drugs, autoimmune therapeutics and novel strategies for transplantation. A University of British Columbia (“UBC”) spin-off, BirchBioMed holds the exclusive, worldwide pharmaceutical license from UBC for two medical therapeutic technologies that mark significant medical breakthroughs in the treatment of fibrosis and certain autoimmune diseases. Initially funded by key strategic donors and government bodies, including the Canadian Institute of Health Research and the Natural Sciences and Engineering Research Council of Canada (the Canadian counterpart of the U.S. National Institutes of Health), BirchBioMed's licensed technology has secured more than $6 million in government and association grants, coupled with additional university resources. It is also the first technology that UBC has advanced from discovery through Phase I clinical trials with support strictly from government/private donations. 

Biotechnology

Clinical Trials

Health Care

Life Sciences

Therapeutics

BirchBioMed Inc.

BirchBioMed Inc.'s headquarters in King City, Canada

Mark S. Nestor

Teresa Brophy Bair

Jon S. Verbeck

Hervé Girsault

Carlos Camozzi

Description

People

Jobs